Skip to main navigation
Invivyd
  • About Us
    • Management Team
    • Board of Directors
  • Our Approach
    • Coronaviruses Background
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
  • Partners
  • Careers
  • Contact
  • About Us
    • Management Team
    • Board of Directors
  • Our Approach
    • Coronaviruses Background
    • Pipeline
    • Publications
  • Clinical Trials
  • Investors & Media
  • Partners
  • Careers
  • Contact
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management
    • Board of Directors
    • Committee Composition
  • Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

Press Releases

Jun 01, 2023
Invivyd to Participate at the Jefferies Healthcare Conference
May 11, 2023
Invivyd Reports First Quarter 2023 Financial Results and Business Highlights
May 04, 2023
Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights
Apr 25, 2023
Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
Apr 25, 2023
Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
Apr 12, 2023
Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer
Mar 30, 2023
Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19
Mar 23, 2023
Invivyd Reports Full Year 2022 Financial Results and Business Highlights
Mar 22, 2023
Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19
Mar 16, 2023
Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 13
Invivyd

For general inquiries:
info@invivyd.com

For medical information
inquiries:
medinfo@invivyd.com

781-819-0080

  • Follow
  • Follow

1601 Trapelo Rd.
Suite 178
Waltham, MA 02451

Privacy Policy   |   Terms of Use   |   Cookie Policy